
COMPASS Pathways (CMPS) Stock Forecast & Price Target
COMPASS Pathways (CMPS) Analyst Ratings
Bulls say
Compass Pathways PLC is poised for growth in the mental health treatment sector, driven by the promising clinical efficacy of its psilocybin formulation, COMP360, which has outperformed Spravato in preliminary data, suggesting a potential competitive advantage. The company's approach to treatment-resistant depression (TRD) not only addresses an underserved patient population but also aligns with broader trends and increased governmental focus on mental health initiatives, particularly for conditions like PTSD. With results indicating the potential for sustained response over longer periods, the commercial prospects for COMP360 appear robust, positioning the company to capitalize on an expanding market for psychedelic therapies.
Bears say
Compass Pathways PLC's stock outlook appears negative due to heightened regulatory scrutiny within the psychedelic sector, exemplified by Lykos Therapeutics' recent adverse AdComm and subsequent complete response letter (CRL), which have collectively contributed to a sell-off of stocks in the industry. The risk of potential failures in clinical trials for Compass's proprietary treatment, COMP360, along with concerns about safety setbacks and the possibility of not securing FDA approval, pose significant challenges to investor confidence. Furthermore, low response rates—evidenced by a only ~20% sustained response in key metrics like the MADRS—raise concerns about the efficacy and market viability of the company’s therapeutic approach.
This aggregate rating is based on analysts' research of COMPASS Pathways and is not a guaranteed prediction by Public.com or investment advice.
COMPASS Pathways (CMPS) Analyst Forecast & Price Prediction
Start investing in COMPASS Pathways (CMPS)
Order type
Buy in
Order amount
Est. shares
0 shares